These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39207799)

  • 1. Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy.
    Alsoudi AF; Wai KM; Koo E; Parikh R; Mruthyunjaya P; Rahimy E
    JAMA Ophthalmol; 2024 Oct; 142(10):972-975. PubMed ID: 39207799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.
    Alsoudi AF; Wai KM; Koo E; Parikh R; Mruthyunjaya P; Rahimy E
    JAMA Ophthalmol; 2024 Jul; 142(7):662-668. PubMed ID: 38842828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
    Martinez-Zapata MJ; Martí-Carvajal AJ; Solà I; Pijoán JI; Buil-Calvo JA; Cordero JA; Evans JR
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD008721. PubMed ID: 25418485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy.
    Azad AD; Chen EM; Hinkle J; Rayess N; Wu D; Eliott D; Mruthyunjaya P; Parikh R
    Ophthalmol Retina; 2021 Feb; 5(2):151-159. PubMed ID: 32693033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
    Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
    Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss to Follow up in Patients with Proliferative Diabetic Retinopathy Treated with Anti-VEGF Therapy and/or Panretinal Photocoagulation in the United States.
    Khurana RN; Wang JC; Zhang S; Li C; Lum F
    Ophthalmol Retina; 2024 Oct; 8(10):953-961. PubMed ID: 38657954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Smith JM; Steel DH
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Treatment Type and Loss to Follow-up With Tractional Retinal Detachment in Proliferative Diabetic Retinopathy.
    Tsui JC; Yu Y; VanderBeek BL
    JAMA Ophthalmol; 2023 Jan; 141(1):40-46. PubMed ID: 36454552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
    JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
    Lin J; Chang JS; Yannuzzi NA; Smiddy WE
    Ophthalmology; 2018 Sep; 125(9):1393-1400. PubMed ID: 29606379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
    Obeid A; Gao X; Ali FS; Talcott KE; Aderman CM; Hyman L; Ho AC; Hsu J
    Ophthalmology; 2018 Sep; 125(9):1386-1392. PubMed ID: 29606377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
    Yang CS; Hung KC; Huang YM; Hsu WM
    J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis.
    Fallico M; Maugeri A; Lotery A; Longo A; Bonfiglio V; Russo A; Avitabile T; Pulvirenti A; Furino C; Cennamo G; Barchitta M; Agodi A; Reibaldi M
    Acta Ophthalmol; 2021 Sep; 99(6):e795-e805. PubMed ID: 33326183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
    Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.
    Sinawat S; Rattanapakorn T; Sanguansak T; Yospaiboon Y; Sinawat S
    Eye (Lond); 2013 Dec; 27(12):1391-6. PubMed ID: 24037235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Glassman AR; Beaulieu WT; Maguire MG; Antoszyk AN; Chow CC; Elman MJ; Jampol LM; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2021 Jul; 139(7):725-733. PubMed ID: 33956075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.